The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 31 July 2000.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 204K)
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lohoff, M.
Right arrow Articles by Mak, T. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lohoff, M.
Right arrow Articles by Mak, T. W.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Leishmaniasis
Hazardous Substances DB
*NITRIC OXIDE
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0022-1007/2000/8/325/ $5.00
The Journal of Experimental Medicine, Volume 192, Number 3, August 7, 2000 325-336


Original Article

Deficiency in the Transcription Factor Interferon Regulatory Factor (IRF)-2 Leads to Severely Compromised Development of Natural Killer and T Helper Type 1 Cells

Michael Lohoffa, Gordon S. Duncanc,d, David Ferricke, Hans-Willi Mittrückerf, Susi Bischofa, Stefan Prechtla, Martin Röllinghoffa, Edgar Schmittg, Andreas Pahlb, and Tak W. Makc,d
a Institut für Klinische Mikrobiologie und Immunologie, Universität Erlangen, 91054 Erlangen, Germany
b Institut für Pharmakologie, Universität Erlangen, 91054 Erlangen, Germany
c Amgen Research Institute, Toronto, Ontario M5G 2C1, Canada
d Ontario Cancer Institute, Department of Immunology, and the Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 2C1, Canada
e Department of Pathology, Department of Microbiology, and the Department of Immunology, School of Veterinary Medicine, University of California at Davis, Davis, California 95616
f Max Planck Institut für Infektionsbiologie, 10117 Berlin, Germany
g Institut für Immunologie, Universität Mainz, 55101 Mainz, Germany

Correspondence to: Tak W. Mak, Ontario Cancer Institute/Amgen Institute, 620 University Ave., Ste. 706, Toronto, Ontario M5G 2C1, Canada. Tel:416-204-2236 Fax:416-204-5300 E-mail:tmak{at}amgen.com.

Interferon (IFN) regulatory factor (IRF)-2 was originally described as an antagonist of IRF-1–mediated transcriptional regulation of IFN-inducible genes. IRF-1-/- mice exhibit defective T helper type 1 (Th1) cell differentiation. We have used experimental leishmaniasis to show that, like IRF-1-/- mice, IRF-2-/- mice are susceptible to Leishmania major infection due to a defect in Th1 differentiation. Natural killer (NK) cell development is compromised in both IRF-1-/- and IRF-2-/- mice, but the underlying mechanism differs. NK (but not NK+ T) cell numbers are decreased in IRF-2-/- mice, and the NK cells that are present are immature in phenotype. Therefore, like IRF-1, IRF-2 is required for normal generation of Th1 responses and for NK cell development in vivo. In this particular circumstance the absence of IRF-2 cannot be compensated for by the presence of IRF-1 alone. Mechanistically, IRF-2 may act as a functional agonist rather than antagonist of IRF-1 for some, but not all, IFN-stimulated regulatory element (ISRE)-responsive genes.

Key Words: interferon regulatory factor, Th1, natural killer cells, Leishmania, interleukin 15


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS